| Aimovig (erenumab-aooe) / Amgen, Novartis |
2019-002224-32: Sense, rhYhm & Networks: the study of how erenumab modulates CHROnic migraine Sentidos, ritmo y conexiones: un estudio de cómo Erenumab® modula la migraña crónica. |
|
|
| Not yet recruiting | 4 | 94 | Europe | Erenumab, Injection, Aimovig | Fundació Hospital Universitari Vall d' Hebrón - Institut de Recerca (VHIR), NOVARTIS | Chronic migraine Migraña crónica, Chronic migraine Migraña crónica, Diseases [C] - Nervous System Diseases [C10] | | | | |
2020-000661-16: The effect of erenumab on the headache inducing properties provocation triggers in migraine patients |
|
|
| Not yet recruiting | 4 | 72 | Europe | Injection, Aimovig | Rigshospitalet Glostrup, Novartis, Rigshospitalet Glostrup | Migraine, Migraine, Diseases [C] - Nervous System Diseases [C10] | | | | |
| Recruiting | 4 | 1000 | Europe | Erenumab, Aimovig | Danish Headache Center | Migraine | 10/22 | 10/22 | | |
| Completed | 4 | 620 | Europe, US, RoW | Erenumab 70 mg, Aimovig, Erenumab 140 mg, Placebo | Amgen | Migraine Headache | 12/22 | 06/23 | | |
2019-002331-28: Biomarker and Genetic Predictors of Erenumab Treatment Response, a Phase 4 Investigational Open-label Study (INTERROGATE) |
|
|
| Not yet recruiting | 4 | 1400 | Europe | AMG 334, AMG 334, Solution for injection in pre-filled pen, Aimovig | Amgen Inc., Amgen Inc. | Episodic or chronic migraine, Migraine, Diseases [C] - Nervous System Diseases [C10] | | | | |
| Terminated | 4 | 32 | US | Eptinezumab, Vyepti, Erenumab, Aimovig®, Onabotulinumtoxin-A, Fremanezumab, Ajovy®, Galcanezumab, Emgality® | H. Lundbeck A/S | Migraine | 02/23 | 04/23 | | |
APOLLON, NCT04084314: Assessment of Prolonged Safety and tOLerability of in Migraine Patients in a Long-term OpeN-label Study |
|
|
| Completed | 4 | 701 | Europe | Erenumab, AMG334; Aimovig | Novartis Pharmaceuticals | Migraine, Migraine Disorders, Migraine Headache | 02/23 | 03/23 | | |
2019-002201-22: Study to assess the long-term safety and tolerability of erenumab in migraine patients |
|
|
| Not yet recruiting | 4 | 640 | Europe | Aimovig, AMG334, Solution for injection in pre-filled pen, Aimovig | Novartis Pharma GmbH, Novartis Pharma GmbH | Migraine prophylaxis, Migraine headaches, Diseases [C] - Nervous System Diseases [C10] | | | | |
2021-000592-36: CGRPR Antagonists and Acute Mountain Sickness CGRPR Antagonisten und akute Bergkrankheit |
|
|
| Not yet recruiting | 4 | 30 | Europe | Erenumab, Solution for injection in pre-filled syringe, Aimovig | Universitätsklinikum Essen, Klinik für Anästhesiologie und Intensivmedizin, Universitätsklinikum Essen, Stiftung Universitätsmedizin Essen, Wilderness Medical Society | Acute Mountain Sickness (AMS) is a constellation of symptoms (headache, anorexia, nausea, vomiting, lightheadedness, and fatigue) occuring in unacclimatized mountaineers ascending too fast, too high Akute Bergkrankheit besteht aus Kopfschmerz, Appetitlosigkeit, Übelkeit, Erbrechen, Benommenheit und Müdigkeit und tritt bei nichtakklimatisierten Bergsteigern auf, die zu schnell in zu große Höhe aufsteigen, Acute Mountain Sickness (AMS) is a constellation of symptomes (headache, nausea, lightheadedness, fatigue, and poor sleep) occuring in unacclimatized mountaineers ascending too fast, too high Akute Bergkrankheit besteht aus Kopfschmerz, Übelkeit, Verwirrtheit, Müdigkeit und Schlaflosigkeit und tritt bei nichtakklimatisierten Bergsteigern auf, die zu schnell in zu große Höhe aufsteigen, Body processes [G] - Physiological processes [G07] | | | | |
| Completed | 4 | 29 | US | Erenumab Prefilled Syringe, Placebo | David Jang, M.D., Amgen | Facial Pain, Rhinosinusitis | 07/23 | 07/23 | | |
NCT04825678: A Study to Evaluate Treatment Satisfaction With Erenumab in Participants With Migraine |
|
|
| Completed | 4 | 240 | US | Erenumab, AMG 334 | Amgen | Migraine | 09/23 | 09/23 | | |
| Completed | 4 | 512 | Europe, US, RoW | Erenumab, Placebo | Amgen | Migraine | 10/23 | 10/23 | | |
REFORM, NCT04674020: Registry for Migraine - Structural and Functional MRI Before and After Erenumab Treatment |
|
|
| Recruiting | 4 | 250 | Europe | Erenumab, Aimovig | Danish Headache Center | Migraine, Headache | 07/25 | 07/25 | | |
NCT04592952: Hypersensitivity to CGRP as a Predictive Biomarker of Migraine Prevention With Erenumab |
|
|
| Recruiting | 4 | 400 | Europe | Calcitonin Gene-Related Peptide, CGRP, Erenumab, Aimovig | Danish Headache Center | Migraine | 08/25 | 08/25 | | |
NCT06411067: Investigational Use of Erenumab for the Treatment of Fibromyalgia Pain |
|
|
| Terminated | 3 | 5 | US | Erenumab, Saline | United States Naval Medical Center, Portsmouth | Fibromyalgia | 05/22 | 05/22 | | |
| Active, not recruiting | 3 | 557 | RoW | Erenumab, AMG334, Placebo | Novartis Pharmaceuticals | Migraine | 08/21 | 06/24 | | |
|
|
| Recruiting | 3 | 456 | Europe, Canada, Japan, US, RoW | Erenumab Dose 1, AMG334, Aimovig®, Erenumab Dose 2, AMG 334, Erenumab Dose 3, Placebo | Amgen, Novartis | Migraine | 03/26 | 02/27 | | |
| Active, not recruiting | 3 | 284 | Europe, Canada, Japan, US, RoW | Erenumab Dose 1, AMG 334, Aimovig®, Erenumab Dose 2, Erenumab Dose 3, Placebo | Amgen, Novartis | Migraine | 01/25 | 01/26 | | |
2018-003943-46: Investigation on the effect and tolerability of erenumab in posttraumatic headache Undersøgelse af effekten og tolerabilitet af erenumab ved posttraumatisk hovedpine |
|
|
| Not yet recruiting | 2 | 100 | Europe | Aimovig | Danish Headache Center, Novartis | Post-traumatic headache Post-traumatisk hovedpine, Headache after concussion Hovedpine efter et hovedtraume, Diseases [C] - Nervous System Diseases [C10] | | | | |
2020-004399-16: Efficacy of Erenumab in the preventive treatement of chronic cluster headache (painful headache attacks):A 10 week clinical trial, which will be performed at multiple (=multicentric) trial centers (e.g. hospitals, doctors office).Patients will be assigned / allocated on random basis (=randomization) to either the experimental group (Erenumab) or control group (Placebo). Neither the patient nor the treating physician knows if the patient receives Erenumab or Placebo (double-blind) |
|
|
| Not yet recruiting | 2 | 118 | Europe | Injection, Aimovig | Charité - Universitätsmedizin Berlin, Novartis Pharma GmbH | chronic cluster headache, Recurrent, severe, painful (one-sided) headache attacks, Diseases [C] - Nervous System Diseases [C10] | | | | |
2019-003971-20: An open label study to evaluate the efficacy and tolerability of erenumab in the management of persistent redness and flushing in rosacea |
|
|
| Not yet recruiting | 2 | 30 | Europe | Injection, Aimovig (Erenumab) | Rigshospitalet Glostrup, Novartis, Rigshospitalet Glostrup | Rosacea, Rosacea, Diseases [C] - Skin and Connective Tissue Diseases [C17] | | | | |
2019-000848-95: Investigation on the effect and tolerability of erenumab in trigeminal neuralgia Undersøgelse af effekten og tolerabilitet af erenumab ved trigeminusneuralgi |
|
|
| Not yet recruiting | 2 | 80 | Europe | Solution for injection, Aimovig | Dansk Hovedpine Center, Neurologisk Klinik, Rigshospitalet - Glostrup, Novartis | Trigeminal neuralgia Trigeminusneuralgi, Trigeminal neuralgia is a painful neuropathic disorder characterized by stabbing, intense, touch-evoked pain attacks in the face. Trigeminusneuralgi er en alvorlig ansigtssmertelidelse med unilaterale svære stikkende, jagende og/eller skarpe smerter af få sekunders varighed der er lokaliseret i ansigtet., Diseases [C] - Nervous System Diseases [C10] | | | | |
| Completed | 2 | 101 | Europe | Erenumab, AMG 334, Placebo | Charite University, Berlin, Germany | Cluster Headache, Trigeminal Autonomic Cephalalgias, Headache Disorders, Primary, Brain Disease | 09/23 | 09/23 | | |
NCT04884763: Safety and Efficacy of Erenumab-aooe in Patients With Temporomandibular Disorder |
|
|
| Completed | 2 | 39 | US | Erenumab-aooe (EREN) 140 mg s.c. administered every four weeks for a total of five treatments, Aimovig®, Placebo (EREN-P) s.c. administered every four weeks for a total of five treatments, Placebo | Indiana University, Novartis Pharmaceuticals | Temporomandibular Disorder | 01/24 | 01/24 | | |
NCT04098250: Multidisciplinary Translational Approach to Investigate Mechanisms Predictors & Prevention of Persistent PTH |
|
|
| Recruiting | 2 | 112 | US | Erenumab, Aimovig, Placebo | Mayo Clinic, University of Arizona, Translational Genomics Research Institute, Arizona State University, Phoenix VA Health Care System, United States Department of Defense, Amgen | Post-Traumatic Headache | 08/25 | 08/25 | | |
| Recruiting | 2 | 40 | US | Siltuximab, Sylvant, Erenumab-Aooe, Aimovig, Siltuximab Matching Placebo, Normal Saline, Erenumab-Aooe Matching Placebo | Massachusetts General Hospital, United States Department of Defense, Recordati Rare Diseases | Schwannomatosis, Schwannomas, Pain, Chronic | 03/26 | 11/27 | | |
NCT05049057: Treatment of Acute PTH With a CGRP Receptor mAb in Military Service Members and Civilians With mTBI |
|
|
| Recruiting | 2 | 404 | US | Erenumab 140 Mg/mL Subcutaneous Solution, Aimovig, Placebo | Henry M. Jackson Foundation for the Advancement of Military Medicine | Posttraumatic Headache, Mild Traumatic Brain Injury | 05/26 | 05/27 | | |
| Recruiting | 1 | 24 | | Single dose of 70 mg Erenumab SC injection ;Single dose of 140 mg Erenumab SC injection | West China Hospital; China Novartis Institutes for BioMedical Research, China Novartis Institutes for BioMedical Research | Migraine | | | | |
| Recruiting | N/A | 2842 | US | erenumab-aooe, Aimovig® | Amgen | Migraine | 10/27 | 10/27 | | |
NCT04452929: The Effect of Anti-calcitonin Gene-related Peptide (CGRP) Receptor Antibodies on the Headache Inducing Properties of CGRP and Cilostazol in Migraine Patients |
|
|
| Recruiting | N/A | 72 | Europe | Erenumab, Aimovig®, Placebo, Saline placebo, Calcitonin gene-related peptide, Cilostazol | Danish Headache Center, Novartis Pharmaceuticals | Migraine, Migraine Without Aura, Migraine With Aura | 02/22 | 07/22 | | |
| Completed | N/A | 40 | Europe | Blood sampling for microRNA testing | University of L'Aquila, Novartis | Migraine | 12/22 | 04/23 | | |
| Completed | N/A | 16 | Europe | Levcromakalim, Placebo | Danish Headache Center, Novartis | Migraine Without Aura | 06/23 | 06/23 | | |
NCT04788667: Effectiveness of a Health Education Programme for Prevention of Chronic Migraine: A Randomized Clinical Trial |
|
|
| Completed | N/A | 48 | Europe | A health education programme using a telerehabilitation platform, Regular pharmacological treatment provided by their neurologists (Fremanezumab o Erenumab), Regular pharmacological treatment provided by their neurologists (Botulinum Toxin) | Universidad de Zaragoza, Universidad San Jorge, Hospital Clínico Universitario Lozano Blesa | Chronic Migraine | 04/24 | 07/24 | | |
| Completed | N/A | 16 | Europe | Sildenafil, Placebo | Danish Headache Center, Novartis | Migraine Without Aura | 10/23 | 10/23 | | |
| Recruiting | N/A | 120 | Europe | Erenumab, Aimovig®, Galcanezumab, Emgality®, Fremanezumab, Ajovy® | Medical University of Vienna | Episodic Migraine, Chronic Migraine | 12/25 | 12/26 | | |
NCT06212661: Migraine Medication Effects on Urinary Symptoms |
|
|
| Enrolling by invitation | N/A | 200 | US | Ubrogepant, Ubrelvy, Rimegepant, Nurtec, Atogepant, Qulipta, Eptinezumab, Vyepti, Fremanezumab, Ajovy, Galcanezumab, Emgality, Erenumab, Aimovig, Botulinum toxin A, Botox | The Cleveland Clinic | Overactive Bladder, Bladder Pain Syndrome, Migraine Disorders, Overactive Bladder Syndrome, Overactive Detrusor, Migraine, Interstitial Cystitis | 05/25 | 05/26 | | |
| Recruiting | N/A | 200 | RoW | erenumab | Novartis Pharmaceuticals | Migraine | 03/25 | 03/25 | | |
| Recruiting | N/A | 60 | | None; None | Guangzhou United Family Hospital; Guangzhou United Family Hospital, self-financing | migraine | | | | |
NCT05281770: Monoclonal CGRP Antibodies for Migraine Prevention - a Nationwide Real Life Study |
|
|
| Recruiting | N/A | 1500 | Europe | Erenumab, Fremanezumab, Galcanezumab | Austrian Migraine Registry Collaboration, Medical University of Vienna, Medical University Innsbruck, Austrian Headache Society | Migraine, Migraine With Aura, Migraine Without Aura, Chronic Migraine, Episodic Migraine | 09/25 | 12/25 | | |
